RecruitingNot ApplicableNCT06322056

Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney Disease


Sponsor

Yonsei University

Enrollment

642 participants

Start Date

May 13, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to prevent kidney disease progression in adults with advanced chronic kidney disease (estimated glomerular filtration rate \[eGFR\] between 15-45 mL/min/1.73 m2) using intensive blood pressure control and intensive lipid management with 2X2 factorial design.


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring whether more aggressive lowering of blood pressure and cholesterol can slow the progression of advanced chronic kidney disease (CKD). Researchers will compare standard treatment targets against lower targets to see which approach better preserves kidney function. **You may be eligible if:** - You are at least 19 years old - You have chronic kidney disease diagnosed at least 3 months ago, with a moderately reduced kidney filtration rate (eGFR 15–45) - Your systolic blood pressure (the top number) is above 130 mmHg - Your LDL cholesterol is 100 mg/dL or higher **You may NOT be eligible if:** - You have resistant high blood pressure not controlled despite 4 or more medications - You have a known secondary cause of high blood pressure - You have had a kidney denervation procedure - You have kidney inflammation requiring immune-suppressing drugs - You have polycystic kidney disease (autosomal dominant type) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntensive control of SBP and intensive control of LDL-C

Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.

DRUGIntensive control of SBP and standard control of LDL-C

Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.

DRUGStandard control of SBP and intensive control of LDL-C

Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.

DRUGStandard control of SBP and standard control of LDL-C

Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.


Locations(1)

Severance Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06322056


Related Trials